Valuation: U.S. Stem Cell, Inc.

Market Cap 661 576.39 544.25 494.22 925.96 63.43K 929.83 6.52K 2.52K 32.25K 2.48K 2.43K 104K P/E 2021
-0.84x
P/E 2022 -0.99x
Enterprise Value 10.08M 8.79M 8.3M 7.54M 14.12M 967M 14.18M 99.42M 38.36M 492M 37.87M 37.02M 1.58B EV / Sales 2021
59.5x
EV / Sales 2022 160x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.01
10 years 0
Extreme 1.0E-6
0.18
Manager TitleAgeSince
Chief Executive Officer 60 24/06/2010
Director TitleAgeSince
Chairman - 02/11/2010
Director/Board Member 60 17/08/2011
Director/Board Member 75 28/08/2013
Date Insider Type Main position Quantity % Market Cap. Importance
25/04/22 Free

Director

2,500,000 0.5198%
25/04/22
Northstar Biotech Group LLC
OtherCompany 0 0% -
18/03/22 Free

Director

50,000,000 10.3959%
Change 5-day change 1-year change 3-year change Capi.($)
-99.00%0.00% - - 661
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
+0.50%+7.13%+33.27%+16.01% 26.34B
-3.21%-7.27%-17.10%+356.10% 26.21B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
+2.12%-5.86%+161.58%+329.34% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.24B
Average -10.09%+1.57%+36.57%+208.32% 27.48B
Weighted average by Cap. -0.28%+1.49%+35.68%+148.22%

Financials

2021 2022
Net sales 201K 175K 165K 150K 281K 19.26M 282K 1.98M 764K 9.79M 754K 737K 31.51M 82.05K 71.55K 67.56K 61.35K 115K 7.87M 115K 809K 312K 4M 308K 301K 12.88M
Net income -3.29M -2.87M -2.71M -2.46M -4.61M -315M -4.62M -32.42M -12.51M -160M -12.35M -12.08M -516M -2.86M -2.49M -2.35M -2.14M -4M -274M -4.02M -28.19M -10.88M -139M -10.74M -10.5M -449M
Net Debt 8.93M 7.79M 7.35M 6.68M 12.51M 857M 12.56M 88.06M 33.98M 436M 33.54M 32.79M 1.4B 10.08M 8.79M 8.3M 7.54M 14.12M 967M 14.18M 99.41M 38.36M 492M 37.86M 37.02M 1.58B
Logo U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor - 1 or SDF-1 protein. The Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
Employees
11
Date Price Change Volume
17/09/26 $0.000001 -99.00% 50,000
  1. Stock Market
  2. Stocks
  3. USRM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!